Treatment of migraines can be complicated by cardiovascular (CV) risk factors. In this phase II/III safety study with adults with migraine and CV risk factors, rimegepant showed favorable safety and tolerability, even in the presence of moderate to high CV risk. Dr. David True, Medical Director at Clinvest Research, a Headlands Research site, co-authored the research.
Read the full article, published in Pain and Therapy.